Contact history | |||
The history of contact with confirmed patients | 60 (42.0%) | 46 (41.8%) | 14 (42.4%) |
The history of contact with epidemic area | 70 (49.0%) | 54 (49.1%) | 16 (48.5%) |
Unknown | 9 (6.3%) | 6 (5.5%) | 3 (9.1%) |
Both | 4 (2.8%) | 4 (3.6%) | 0 (0%) |
Temperature (˚C) | |||
<37.5 | 1 (0.7%) | 1 (0.9%) | 0 (0%) |
37.5 - 38 | 7 (4.9%) | 7 (6.4%) | 0 (0%) |
38 - 38.5 | 39 (27.3%) | 29 (26.4%) | 10 (30.3%) |
38.5 - 39 | 26 (18.2%) | 19 (17.3%) | 7 (21.2%) |
39 - 40 | 32 (22.4%) | 20 (18.2%) | 12 (36.4%) |
>40 | 1 (0.7%) | 1 (0.9%) | 0 (0%) |
Unknown | 37 (25.9%) | 33 (30.0%) | 4 (12.1%) |
Clinical symptoms | |||
Fever | 105 (73.4%) | 76 (53.1%) | 29 (20.1%) |
Coughing of phlegm | 41 (28.7%) | 30 (27.3%) | 11 (33.3%) |
Dry cough | 42 (29.4%) | 30 (27.3%) | 12 (36.4%) |
Yellow sputum | 8 (5.6%) | 6 (5.5%) | 2 (6.1%) |
Sore throat | 15 (10.5%) | 12 (10.9%) | 3 (9.1%) |
Nasal obstruction | 8 (5.6%) | 8 (7.3%) | 0 (0%) |
Muscle soreness | 14 (9.8%) | 11 (10.0%) | 3 (9.1%) |
Weak | 37 (25.9%) | 31 (28.2%) | 6 (18.2%) |
Chest distress | 25 (17.5%) | 17 (15.5%) | 8 (24.2%) |
Coexisting disorders | |||
hypertension | 20 (14.0%) | 15 (13.6%) | 5 (15.2%) |
diabetes | 12 (8.4%) | 7 (6.4%) | 5 (15.2%) |
COPD | 3 (2.1%) | 2 (1.8%) | 1 (3.0%) |
The incubation period (days) |
|
|
|
<3 | 3 (2.1%) | 3 (2.7%) | 0 (0%) |
3 - 6 | 10 (7%) | 9 (7.3%) | 1 (3.0%) |
6 - 9 | 10 (7%) | 9 (8.1%) | 1 (3.0%) |
9 - 12 | 6 (4.2%) | 3 (2.7%) | 3 (9.1%) |
>15 | 4 (2.8%) | 4 (3.6%) | 0 (0%) |
Unknown | 110 (76.9%) | 82 (74.5%) | 28 (84.8%) |
Treatment delay | |||
<1 | 49 (34.3%) | 8 (24.2%) | 41 (37.3%) |
1 - 2 | 40 (28.0%) | 8 (24.2%) | 32 (29.1%) |
2 - 5 | 22 (15.4%) | 6 (18.2%) | 16 (14.5%) |
5 - 10 | 16 (11.2%) | 7 (21.2%) | 9 (8.2%) |
>10 | 2 (1.4%) | 2 (6.1%) | 0 (0%) |
Unknown | 14 (9.8%) | 2 (6.1%) | 12 (10.9%) |